Luxembourg lets Israel bond prospectus expire, leaving EU borrowing uncertain
Luxembourg's financial regulator, the CSSF, decided in May not to renew approval for the Israel bond prospectus beyond its August 31 expiry date. This means Israel can no longer issue bonds in the EU market unless another EU country takes over the prospectus approval. The decision follows similar action by Ireland, which previously served as the regulatory home for Israeli bonds. Israel has raised significant funds through these bonds, including $4.5 billion between October 2023 and January 2025, according to Amnesty International. The move comes amid ongoing criticism of Israel's military actions in Gaza and other territories, with human rights groups urging EU states to stop facilitating such bonds. Israel still has access to other markets, notably the US, where it raises about $2.5 billion annually.
Comments 0
Discuss this event in persistent threads. Live chat remains separate.
What we know
Luxembourg's financial regulator, the CSSF, decided in May not to renew approval for the Israel bond prospectus beyond its August 31 expiry date.
▤ 1 sources›
Israel will need to find another EU country to approve the prospectus to continue issuing bonds in the EU market.
▤ 1 sources›
Ireland previously served as the regulatory home for Israeli bonds but did not renew its approval in September 2025.
▤ 1 sources›
Israel Bonds issued in the EU raise about $2.5 billion a year, according to Israel's Ministry of Finance.
▤ 1 sources›
Israel still has access to other markets, notably the US, where it raises about $2.5 billion annually.
▤ 1 sources›
Israel raised $4.5 billion through Israel Bonds between October 2023 and January 2025, according to Amnesty International.
▤ 1 sources›
The prospectus expired on Monday, August 31, 2026.
▤ 1 sources›
Open any source to inspect its original language, when DoseFix received it, and the claims it supports.
Luxembourg drops approval for Israel bonds issue: What that means
aljazeera.com · EN · Published · Received
No comments yet. Start the conversation.